David Michael Johnson, Director at Zentalis Pharmaceuticals, Inc. (ZNTL), sold 21,367 shares at $52.72 ($1.1M) on 2020-12-02, disclosed to the SEC on 2020-12-03.
Open-market sale of $1.1M ZNTL by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $49.80 | 1,600 | $80K | 7.3% |
| 2 | $50.82 | 3,868 | $197K | 17.9% |
| 3 | $50.82 | 3,868 | $197K | 17.9% |
| 4 | $51.61 | 4,603 | $238K | 21.7% |
| 5 | $51.61 | 4,603 | $238K | 21.7% |
| 6 | $52.72 | 2,825 |
| $149K |
| 13.6% |
| Total | $51.34 avg | 21,367 | $1.1M | 100% |
| Filing → |
| AURA | BUY | 2023-11-09 | $1.1M | — | Filing → |
| AURA | BUY | 2023-10-05 | $225K | — | Filing → |
| AURA | BUY | 2023-01-09 | $21K | — | Filing → |